Author's response to reviews

Title: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Authors:

Jessica N McAlpine (mcalpine_j@yahoo.com)
Kimberly C Wiegand (KWiegand@cw.bc.ca)
Russell Vang (rvang@jhmi.edu)
Brigitte M Ronnett (bronnett@jhmi.edu)
Anna Adamiak (aadamiak2005@meds.uwo)
Martin Koebel (martin.koebel@vch.ca)
S E Kalloger (skalloger@mac.com)
Kenneth D Swenerton (KSwener@bccancer.bc.ca)
David G Huntsman (dhuntsma@bccancer.bc.ca)
C Blake Gilks (blake.gilks@vch.ca)
Dianne M Miller (dianne.miller@vch.ca)

Version: 4 Date: 1 October 2009

Author's response to reviews: see over
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy, McAlpine et al.

Thanks again for the suggestions regarding our manuscript. The manuscript has been changed with track changes apparent.

Referee/reviewer #2: No changes requested nor suggested.

Response to referee/reviewer #3:

Our response to Reviewer 3 Comments regarding the use of Fisher’s exact test and our statistical analyses:

The Fisher’s Exact Test was used to compare the proportion of patients who progressed with regard to HER2 status. We felt that this approach to the analysis was justified given the small sample size with an unequal population distribution. However, use of the FE and the aforementioned comparison does not add any new information to the manuscript that is not already covered by the Kaplan-Meier analysis therefore it has been removed from this draft.

We have added analyses to compare the HER2positive and HER2 negative groups for the parameters of interest(Table 1).

Minor details/corrections and comments raised by Dr. Stahl:

We have clarified the abbreviations of PFS and OS in the text. Similarly, a typo of “twothree” page 8 corrected. In our final conclusions section the statement has been softened. As to whether or not HER2 amplification may be herald an improved prognosis it is the authors belief that this may ultimately prove to be true but cannot be concluded from the cases we have at present.

Please do not hesitate to contact us with questions.

Sincerely,

Jessica McAlpine, MD

Assistant Professor
University of British Columbia
Department of Gynecology and Obstetrics
Division of Gynecologic Oncology
Academic Ambulatory Care Center
2775 Laurel St.
Vancouver, BC V5Z-1M9